{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:12Z","timestamp":1793677272012,"version":"4.5.1"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.blre.2024.101251","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T18:18:00Z","timestamp":1732645080000},"page":"101251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection"],"prefix":"10.1016","volume":"69","author":[{"given":"Geoffrey","family":"Shouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1936","key":"10.1016\/j.blre.2024.101251_bb0005","article-title":"Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets","volume":"8","author":"Cuesta-Mateos","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"10.1016\/j.blre.2024.101251_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172641","article-title":"Hematological malignancies and molecular targeting therapy","volume":"862","author":"Shimada","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0035","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101251_bb0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0000000000000966","article-title":"Update on bi-specific monoclonal antibodies for blood cancers","volume":"35","author":"Shouse","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.blre.2024.101251_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"10.1016\/j.blre.2024.101251_bb0050","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2217\/fon.15.84","article-title":"Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia","volume":"11","author":"Bumma","year":"2015","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0055","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.blre.2024.101251_bb0060","series-title":"Bispecific Antibody Toxicity. StatPearls. Treasure Island (FL) With Ineligible Companies. Disclosure: Poornima Ramadas Declares No Relevant Financial Relationships With Ineligible Companies","author":"Chennapragada","year":"2024"},{"issue":"16","key":"10.1016\/j.blre.2024.101251_bb0065","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.blre.2024.101251_bb0075","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/cam4.3731","article-title":"Blinatumomab as first salvage versus second or later salvage in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis","volume":"10","author":"Topp","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2024.101251_bb0080","article-title":"Real-world multicenter experience in tumor Debulking prior to Blinatumomab Administration in Adult Patients with Relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"11","author":"Bonifacio","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0085","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2024.101251_bb0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.18218","article-title":"VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse","volume":"198","author":"Heraudet","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0095","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.blre.2024.101251_bb0100","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.blre.2024.101251_bb0105","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1182\/blood-2022-171751","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101251_bb0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101251_bb0115","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood-2022-157361","article-title":"Single cycle of Blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. Primary endpoint analysis of the Blina-cell trial","volume":"140","author":"Salek","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0120","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0125","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-Centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.blre.2024.101251_bb0130","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101251_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2024.101251_bb0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2024.101251_bb0150","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0155","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101251_bb0160","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bjh.19346","article-title":"Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3","volume":"204","author":"Mohty","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101251_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967676.59550.94","article-title":"S191: Pivotal Phase 2 monumental-1 results of talquetamab (TAL), a GPRC5DXCD3 bispecific antibody (BSAB), for relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Touzeau","year":"2023","journal-title":"Hemasphere"},{"issue":"24","key":"10.1016\/j.blre.2024.101251_bb0170","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101251_bb0175","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab","volume":"90","author":"Lery","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0180","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1182\/blood-2023-189151","article-title":"Symptoms, functioning, and health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with Talquetamab: updated patient-reported outcomes from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Schinke","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0185","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2024.101251_bb0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from majesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous Daratumumab and Lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a Phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0200","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab plus Pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0205","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: phase 3 trial of Talquetamab + Daratumumab \u00b1 Pomalidomide versus Daratumumab + Pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0210","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety Lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0215","first-page":"8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2024.101251_bb0220","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.blre.2024.101251_bb0225","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2024.101251_bb0230","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/1097-0142(19800515)45:10<2627::AID-CNCR2820451023>3.0.CO;2-0","article-title":"Spontaneous regression in non-Hodgkin\u2019s lymphoma","volume":"45","author":"Gattiker","year":"1980","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.blre.2024.101251_bb0235","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2024.101251_bb0240","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2024.101251_bb0245","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.blre.2024.101251_bb0250","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101251_bb0255","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.blre.2024.101251_bb0260","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2024.101251_bb0265","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7360","key":"10.1016\/j.blre.2024.101251_bb0270","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2024.101251_bb0275","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0280","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"7337","key":"10.1016\/j.blre.2024.101251_bb0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.blre.2024.101251_bb0290","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2024.101251_bb0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.blre.2024.101251_bb0305","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101251_bb0310","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent Mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101251_bb0315","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101251_bb0320","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2024.101251_bb0325","article-title":"Thinking \u201coutside the germinal center\u201d: re-educating T cells to combat follicular lymphoma","volume":"61","author":"Kambhampati","year":"2023","journal-title":"Blood Rev"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2023-173692","article-title":"Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0335","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous Mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2024.101251_bb0340","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.blre.2024.101251_bb0345","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0350","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2023-177917","article-title":"Subcutaneous Mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: initial results from the phase II Morningsun study","volume":"142","author":"Flinn","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0355","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2023-179906","article-title":"Subcutaneous (SC) Mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0360","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary findings of a phase Ib\/II trial indicate manageable safety and promising efficacy for Mosunetuzumab in combination with Lenalidomide (M+Len) in previously untreated (1L) follicular lymphoma (FL)","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0365","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2023-180092","article-title":"EPCORE FL-1: phase 3 trial of subcutaneous Epcoritamab with rituximab and Lenalidomide (R 2) vs R 2 alone in patients with relapsed or refractory follicular lymphoma","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0370","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096","article-title":"Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator\u2019s choice in previously untreated follicular lymphoma (OLYMPIA-1)","volume":"42","author":"Birhiray","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0375","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099","article-title":"Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2)","volume":"42","author":"Hardin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7086","article-title":"Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3)","volume":"42","author":"Matasar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0385","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","article-title":"Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): updated analysis from a phase I\/II study","volume":"42","author":"Phillips","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0390","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2023-173946","article-title":"GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating Glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0395","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration Mosunetuzumab plus Polatuzumab Vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0400","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a phase III, multicenter, open label, randomized, controlled study investigating Mosunetuzumab-Lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0405","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2023-174292","article-title":"Early complete responses with Mosunetuzumab monotherapy in treatment-Na\u00efve follicular and marginal zone lymphomas with only low-grade cytokine release syndrome","volume":"142","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0410","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2024.101251_bb0415","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose Expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2024.101251_bb0420","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0425","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1200\/JCO.2024.42.16_suppl.7039","article-title":"Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: subcutaneous epcoritamab monotherapy in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL)","volume":"42","author":"Karimi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0430","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood-2023-174209","article-title":"Mosunetuzumab plus polatuzumab vedotin demonstrates a favorable safety profile and efficacy in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): primary analysis of a phase Ib\/II study","volume":"142","author":"Budde","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0435","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2023-174213","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0440","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2023-180089","article-title":"Subcutaneous Epcoritamab plus Lenalidomide in patients with relapsed\/refractory diffuse large B-cell lymphoma from EPCORE NHL-5","volume":"142","author":"Avivi Mazza","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0445","unstructured":"Jeremy Abramson MK, Mark Hertzberg, Christopher Fox, Charles Herbaux, Maria Fatima De La Cruz Vicente, Huiqiang Huang, Dok Hyun Yoon, Won-Seog Kim, Huilai Zhang, Jan Maciej Zaucha, Haifaa Abdulhaq, William Townsend, Stephen Simko, Victor Orellana-Noia, Richard Ta, Yuying Xie, Martine Kallemeijn, Linda Lundberg, Gareth Gregory. Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-Gemox) for Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO). 2024 European Hematology Association Congress. 2024."},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0450","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1200\/JCO.2024.42.16_suppl.7037","article-title":"Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: updated results from EPCORE NHL-2","volume":"42","author":"Brody","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2024.101251_bb0455","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1200\/JCO.2024.42.16_suppl.7032","article-title":"Epcoritamab + R-DHAX\/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"42","author":"Karimi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0460","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase Ib study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0465","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and Polatuzumab Vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large B-cell lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0470","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2023-188854","volume":"142","author":"Melchardt","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101251_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.blre.2024.101251_bb0480","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstrikova","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101251_bb0485","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"10.1016\/j.blre.2024.101251_bb0490","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.blre.2024.101251_bb0495","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.blre.2024.101251_bb0500","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2024.101251_bb0505","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0510","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0515","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2230888","article-title":"Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy","volume":"55","author":"Qi","year":"2023","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101251_bb0520","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.blre.2024.101251_bb0525","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.blre.2024.101251_bb0530","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2024.101251_bb0535","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101251_bb0540","doi-asserted-by":"crossref","first-page":"308.e301","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of Teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.blre.2024.101251_bb0545","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0550","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1182\/blood-2023-183085","article-title":"Teclistamab in relapsed\/refractory multiple myeloma: real-world outcomes at a single academic center in the Midwest","volume":"142","author":"Stepanovic","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101251_bb0555","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2024.101251_bb0560","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0565","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101251_bb0570","first-page":"8","article-title":"Sequential administration of bispecific antibodies and anti-bcma car-t cell therapy in relapsed\/ refractory multiple myeloma is associated with expansion of cd8 effector clones and high response rates","author":"Fandrei","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2024.101251_bb0580","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.blre.2024.101251_bb0585","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.blre.2024.101251_bb0590","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.blre.2024.101251_bb0595","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.blre.2024.101251_bb0600","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0605","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2023-185035","article-title":"Efficacy of chimeric antigen receptor T-cell therapy is not impaired by previous bispecific antibody treatment in patients with large B-cell lymphoma","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0610","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2023-188444","article-title":"GB261, an Fc-function enabled and CD3 affinity de-tuned CD20\/CD3 bispecific antibody, demonstrated a highly advantageous safety\/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed\/refractory non-hodgkin lymphoma","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0615","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2023-174668","volume":"142","author":"Gaballa","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0620","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2023-187721","article-title":"A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Guru Murthy","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0625","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2023-173302","article-title":"Dose escalation of HLA-A2-WT1 CD3 T-cell bispecific antibody in a phase I study in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0630","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2023-189514","article-title":"AML immunotherapy using a novel Tcrm-based bispecific antibody that targets a leader sequence peptide derived from cathepsin G","volume":"142","author":"Shi","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0635","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2023-186664","article-title":"Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma (RRMM)","volume":"142","author":"Kapoor","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0640","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/blood-2023-180926","article-title":"Safety and preliminary efficacy of sabestomig (AZD7789), an anti-PD-1 and anti-TIM-3 bispecific antibody, in patients with relapsed or refractory classical hodgkin lymphoma previously treated with anti-PD-(L)1 therapy","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0645","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2023-189088","article-title":"The CD38\/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas","volume":"142","author":"Dupuy","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0650","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2023-184797","article-title":"A CD38\/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent for the treatment of older patients with acute myeloid leukemia (AML)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0655","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2023-182150","article-title":"A CD38\/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent in multiple myeloma patients relapsed and\/or refractory (RRMM) to anti-CD38 monoclonal antibodies (mAbs)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0660","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0665","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2023-179061","article-title":"A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and\/or refractory B-cell malignancies","volume":"142","author":"Avivi Mazza","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0670","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2023-181239","article-title":"A phase 1, open-label, dose escalation and dose expansion study of CLN-978 (CD19XCD3XHSA) in patients with relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (B-NHL)","volume":"142","author":"Shouse","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0675","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0680","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.blre.2024.101251_bb0685","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2024.101251_bb0690","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the cooperative group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.blre.2024.101251_bb0695","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.blre.2024.101251_bb0700","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2024.101251_bb0705","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0710","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood-2023-172935","article-title":"Geographic and racial disparities in chimeric antigen receptor-T cells and bispecific antibodies trials access for diffuse large b-cell lymphoma","volume":"142","author":"Shahzad","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101251_bb0715","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood-2023-179050","article-title":"The GLAMM1 study - global access to myeloma medications: potential barriers to chimeric antigen receptors (CART) and T-cell-engaging bispecific antibodies (TCE) globally","volume":"142","author":"Atallah","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101251_bb0720","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1200\/OP.22.00560","article-title":"Increasing racial and ethnic equity, diversity, and inclusion in cancer treatment trials: evaluation of an asco-association of community cancer centers site self-assessment","volume":"19","author":"Guerra","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"19","key":"10.1016\/j.blre.2024.101251_bb0725","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of community cancer centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101251_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100532","article-title":"Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials","volume":"17","author":"Regnante","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"issue":"4","key":"10.1016\/j.blre.2024.101251_bb0735","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1200\/JOP.18.00638","article-title":"US Cancer Centers of excellence strategies for increased inclusion of racial and ethnic minorities in clinical trials","volume":"15","author":"Regnante","year":"2019","journal-title":"J Oncol Pract"},{"issue":"10","key":"10.1016\/j.blre.2024.101251_bb0740","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T11:41:39Z","timestamp":1737286899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":148,"alternative-id":["S0268960X24000845"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101251","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101251"}}